Cytotoxic T lymphocyte antigen 4-immunoglobulin G is a potent adjuvant for experimental allergen immunotherapy

Clinical and Experimental Immunology

Volumn 172, Issue 1, 2013, Pages 113-120

  Maazi, H ^a   Shirinbak, S ^a   den Boef, L E ^a   Fallarino, F ^b   Volpi, C ^b   Nawijn, M C ^a   van Oosterhout, A J M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Adjuvant; Airway hyperreactivity; Allergen immunotherapy; CTLA 4 Ig in allergy

Indexed keywords

ABATACEPT; IMMUNOGLOBULIN E; INDOLEAMINE 2,3 DIOXYGENASE; OVALBUMIN;

ADJUVANT THERAPY; ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; EOSINOPHILIA; IMMUNOSTIMULATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT ALLERGY; T LYMPHOCYTE ACTIVATION; TH2 CELL; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANIMALS; ANTIGENS, CD28; ASTHMA; CYTOKINES; DESENSITIZATION, IMMUNOLOGIC; GENE EXPRESSION; IMMUNE TOLERANCE; IMMUNOCONJUGATES; IMMUNOGLOBULIN E; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OVALBUMIN; T-LYMPHOCYTES, CYTOTOXIC; TH2 CELLS;

EID: 84874993782     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12041     Document Type: Article

References (41)

1. Anandan C, Nurmatov U, van Schayck OC, Sheikh A. Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 2010; 65:152-167.
2. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med 2006; 355:2226-2235.
3. Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol 2010; 125 (2 Suppl. 2):S306-S313.
4. Reha CM, Ebru A. Specific immunotherapy is effective in the prevention of new sensitivities. Allergol Immunopathol (Madr) 2007; 35:44-51.
5. Pajno GB, Barberio G, De LF, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-1397.
6. Niggemann B, Jacobsen L, Dreborg S etal. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006; 61:855-859.
7. Ownby DR, Adinoff AD. The appropriate use of skin testing and allergen immunotherapy in young children. J Allergy Clin Immunol 1994; 94:662-665.
8. Casale TB. Status of immunotherapy: current and future. J Allergy Clin Immunol 2004; 113:1036-1039.
9. Francis JN, Durham SR. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol 2004; 4:543-548.
10. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005; 6:345-352.
11. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1:220-228.
12. Carreno BM, Bennett F, Chau TA etal. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 2000; 165:1352-1356.
13. Alegre ML, Fallarino F. Mechanisms of CTLA-4-Ig in tolerance induction. Curr Pharm Des 2006; 12:149-160.
14. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174:561-569.
15. Rigby MR, Trexler AM, Pearson TC, Larsen CP. CD28/CD154 blockade prevents autoimmune diabetes by inducing nondeletional tolerance after effector T-cell inhibition and regulatory T-cell expansion. Diabetes 2008; 57:2672-2683.
16. Ariyan C, Salvalaggio P, Fecteau S etal. Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J Immunol 2003; 171:5673-5677.
17. Guo Z, Wang J, Dong Y etal. Long-term survival of intestinal allografts induced by costimulation blockade, busulfan and donor bone marrow infusion. Am J Transplant 2003; 3:1091-1098.
18. Alvarez-Quiroga C, Abud-Mendoza C, Doniz-Padilla L etal. CTLA-4-Ig therapy diminishes the frequency but enhances the function of treg cells in patients with rheumatoid arthritis. J Clin Immunol 2011; 31:588-595.
19. Furuzawa-Carballeda J, Lima G, Uribe-Uribe N etal. High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. Transplant Proc 2010; 42:3489-3496.
20. Deurloo DT, van Oosterhout AJ. Role of T cell co-stimulation in murine models of allergic asthma. Clin Exp Allergy 2004; 34:17-25.
21. Rudd CE, Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol 2003; 3:544-556.
22. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 2007; 7:817-823.
23. Taher YA, Piavaux BJ, Gras R etal. Indoleamine 2, 3-dioxygenase-dependent tryptophan metabolites contribute to tolerance induction during allergen immunotherapy in a mouse model. J Allergy Clin Immunol 2008; 121:983-991.
24. Bussmann C, Xia J, Allam JP, Maintz L, Bieber T, Novak N. Early markers for protective mechanisms during rush venom immunotherapy. Allergy 2010; 65:1558-1565.
25. Taher YA, van Esch BC, Hofman GA, Henricks PA, van Oosterhout AJ. 1Alpha, 25-dihydroxyvitamin D3 potentiates the beneficial effects of allergen immunotherapy in a mouse model of allergic asthma: role for IL-10 and TGF-beta. J Immunol 2008; 180:5211-5221.
26. Deurloo DT, van Esch BCAM, Hofstra CL, Nijkamp FP, van Oosterhout AJM. CTLA4-IgG reverses asthma manifestations in a mild but not in a more 'severe' ongoing murine model. Am J Respir Cell Mol Biol 2001; 25:751-760.
27. Grohmann U, Volpi C, Fallarino F etal. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 2007; 13:579-586.
28. Shirinbak S, Taher YA, Maazi H etal. Suppression of Th2-driven airway inflammation by allergen immunotherapy is independent of B cell and Ig responses in mice. J Immunol 2010; 185:3857-3865.
29. van Rijt LS, Kuipers H, Vos N, Hijdra D, Hoogsteden HC, Lambrecht BN. A rapid flow cytometric method for determining the cellular composition of bronchoalveolar lavage fluid cells in mouse models of asthma. J Immunol Methods 2004; 288:111-121.
30. Maazi H, Shirinbak S, Bloksma N, Nawijn MC, van Oosterhout AJ. Iron administration reduces airway hyperreactivity and eosinophilia in a mouse model of allergic asthma. Clin Exp Immunol 2011; 166:80-86.
31. Grohmann U, Orabona C, Fallarino F etal. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3:1097-1101.
32. Fallarino F, Bianchi R, Orabona C etal. CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice. J Exp Med 2004; 200:1051-1062.
33. Davis PM, Nadler SG, Stetsko DK, Suchard SJ. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol 2008; 126:38-47.
34. Wing K, Onishi Y, Prieto-Martin P etal. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322:271-275.
35. Van Oosterhout AJ, Van Esch B, Hofman G etal. Allergen immunotherapy inhibits airway eosinophilia and hyperresponsiveness associated with decreased IL-4 production by lymphocytes in a murine model of allergic asthma. Am J Respir Cell Mol Biol 1998; 19:622-628.
36. Coffer PJ, Burgering BM. Forkhead-box transcription factors and their role in the immune system. Nat Rev Immunol 2004; 4:889-899.
37. Hill M, Zagani R, Voisine C, Usal C, Anegon I. Nitric oxide and indoleamine 2, 3-dioxygenase mediate CTLA4Ig-induced survival in heart allografts in rats. Transplantation 2007; 84:1060-1063.
38. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192:1213-1222.
39. Kerstan A, Albert C, Klein D, Brocker EB, Trautmann A. Wasp venom immunotherapy induces activation and homing of CD4(+)CD25(+) forkhead box protein 3-positive regulatory T cells controlling T(H)1 responses. J Allergy Clin Immunol 2011; 127:495-501.
40. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009; 21:1105-1111.
41. Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009; 229:307-321.